Jacopo Sabbatinelli, Patrick Orlando, Roberta Galeazzi, Sonia Silvestri, Ilenia Cirilli, Fabio Marcheggiani, Phiwayinkosi V Dludla, Angelica Giuliani, Anna Rita Bonfigli, Laura Mazzanti, Fabiola Olivieri, Roberto Antonicelli, Luca Tiano
In this randomized, double-blind, single-center trial (ANZCTR number ACTRN12619000436178) we aimed to investigate changes in endothelium-dependent vasodilation induced by ubiquinol, the reduced form of coenzyme Q10 (CoQ10), in healthy subjects with moderate dyslipidemia. Fifty-one subjects with low-density lipoprotein (LDL) cholesterol levels of 130-200 mg/dL, not taking statins or other lipid lowering treatments, moderate (2.5%-6.0%) endothelial dysfunction as measured by flow-mediated dilation (FMD) of the brachial artery, and no clinical signs of cardiovascular disease were randomized to receive either ubiquinol (200 or 100 mg/day) or placebo for 8 weeks...
April 15, 2020: Nutrients